Agarwal presented the results of one of his many Phase III trials at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The trial looked at the effectiveness of adding TALZENNA to XTANDI, the standard treatment where an androgen receptor blocker stops the male hormones from feeding the cancer. On the other hand, TALZENNA is a PARP inhibitor commonly used in treating breast cancer.
In the study, treatment plan for each patient was randomly selected and the clinical trials team monitored and made comparisons of side effects and results between two groups - those who received the two drugs, and those who received XTANDI plus placebo pill.Results showed that the combined therapy regimen exhibited significant development in radiographic progression-free survival. TALZENNA, combined with XTANDI, reduces the risk of disease progression or death by 37%.